Montelukast Accord (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and eosinophils. This inhibition prevents leukotrienes D4, E4 and related mediators from triggering inflammation, mucus production and bronchial smooth‑muscle contraction, thereby helping keep the airways open.

The appropriate dose of Montelukast Accord is determined by the prescribing healthcare professional based on the patient’s age, clinical condition and response to therapy. Dosage recommendations are provided in the product labeling, but the final regimen is set by the prescriber.

Montelukast is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies the potential risk. Small amounts are excreted in breast milk, so a risk‑benefit assessment is required for nursing mothers.

To order Montelukast Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, which works by blocking leukotriene‑mediated inflammation, whereas inhaled corticosteroids reduce airway inflammation through a different pathway and short‑acting bronchodilators provide rapid relief of bronchospasm. Montelukast is taken orally once daily and is often used as an add‑on therapy or for patients who prefer a non‑inhaled option.

Montelukast Accord should be stored below 25 °C in a dry place. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

Montelukast Accord is administered orally, usually as a tablet taken with or without food. The exact timing (e.g., in the evening) and whether it should be taken with a meal are determined by the prescribing clinician based on the individual’s therapeutic plan.

Serious adverse reactions, although rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury and neuropsychiatric events like agitation, depression or suicidal thoughts. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash with blistering, persistent abdominal pain, or any sudden change in mood.

Montelukast Accord should be avoided in individuals with known hypersensitivity to montelukast sodium or any component of the formulation. Caution is advised for patients with severe hepatic impairment, and it is not recommended for use in children under six months of age unless specifically directed by a specialist.